<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22193989</article-id><article-id pub-id-type="pmc">3378839</article-id><article-id pub-id-type="publisher-id">1189</article-id><article-id pub-id-type="doi">10.1007/s00262-011-1189-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tel</surname><given-names>Jurjen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hato</surname><given-names>Stanleyson V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Torensma</surname><given-names>Ruurd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buschow</surname><given-names>Sonja I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Figdor</surname><given-names>Carl G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lesterhuis</surname><given-names>W. Joost</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>de Vries</surname><given-names>I. Jolanda M.</given-names></name><address><phone>+31-24-3617600</phone><fax>+31-24-3640339</fax><email>J.deVries@ncmls.ru.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Medical Oncology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Pediatric Oncology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>12</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>12</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2012</year></pub-date><volume>61</volume><issue>7</issue><fpage>1101</fpage><lpage>1111</lpage><history><date date-type="received"><day>27</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><p>It has become evident that the tumor microenvironment plays a pivotal role in the maintenance of cancerous growth. One of the acquired functions of the tumor microenvironment is the suppression of immune responses. Indeed, blocking the inhibitory pathways operational in the microenvironment results in enhanced T-cell-dependent, anti-tumor immunity. Chemotherapeutic drugs not only directly kill tumor cells but also shape the tumor microenvironment and potentiate anti-tumor immunity. Here, we demonstrate that the chemotherapeutic compound oxaliplatin acts as a double-edged sword. Besides killing tumor cells, oxaliplatin bolsters immunosuppressive pathways, resulting in decreased activation of T cells by human plasmacytoid dendritic cells (pDCs). Exposure to oxaliplatin markedly increased expression of the T-cell inhibitory molecule programmed death receptor-ligand 1 (PD-L1) on human pDCs and also TLR9-induced IFN&#x003b1; secretion. Furthermore, oxaliplatin decreased TLR-induced STAT1 and STAT3 expression, and NF-&#x003ba;B-mediated responses. The oxaliplatin induced upregulation of PD-L1 and downregulation of costimulatory molecules CD80 and CD86 resulted in decreased T-cell proliferation. Our results demonstrate that platinum-based anticancer drugs adapt TLR-induced signaling in human pDCs and myeloid DCs (mDCs), thereby downgrading their immunostimulatory potential.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00262-011-1189-x) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Blood DC subsets</kwd><kwd>PD-L1</kwd><kwd>TLR</kwd><kwd>Oxaliplatin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APC) of the immune system. Upon infection or inflammation, immature DCs are activated and differentiate into mature DCs that instruct and activate B and T lymphocytes, the mediators of adaptive immunity [<xref ref-type="bibr" rid="CR1">1</xref>]. Two major types of DCs circulate in peripheral blood, myeloid DCs (mDCs) and plasmacytoid (pDCs). These DC subsets express a divergent set of surface molecules and have distinct functions [<xref ref-type="bibr" rid="CR2">2</xref>]. In addition to scavenging pathogens and presenting antigens, DCs secrete a large array of cytokines, which are all vital for proper functioning of both the acquired and the innate immune system.</p><p>Although these DC subsets reside in the peripheral blood, they also infiltrate solid tumors, such as breast cancer [<xref ref-type="bibr" rid="CR3">3</xref>], head and neck cancer [<xref ref-type="bibr" rid="CR4">4</xref>] and ovarian cancer [<xref ref-type="bibr" rid="CR5">5</xref>]. Soluble factors secreted by the tumor and necrotic tumor material prevent differentiation and activation of infiltrating DCs, including pDCs [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. These findings have been correlated with poor prognosis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, Curiel et al. demonstrated that in human ovarian cancer, infiltrating DCs express the immunosuppressive receptor program death ligand 1 (PD-L1 also known as B7-H1 or CD274) [<xref ref-type="bibr" rid="CR10">10</xref>]. PD-L1 negatively regulates the delicate balance between T-cell activation and inhibition through interaction with its receptor program death receptor 1 (PD-1) resulting in suppressed T-cell activation [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] and maintenance of the immunosuppressive environment. The negative regulation of T-cell activation via PD-1/PD-L1 is also supported by studies using blocking antibodies to PD-L1 performed on DCs [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. The importance of this pathway is further highlighted in studies showing that blockade of the PD-1/PD-L pathway results in enhanced tumor-specific T-cell expansion and activation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. PDCs and mDCs circulating in the blood do not or hardly express PD-L1. However, upon TLR-induced activation or stimulation with type I or type II IFNs, PD-L1 is upregulated on pDCs and mDCs [<xref ref-type="bibr" rid="CR18">18</xref>]. This upregulation has been linked to decreased T-cell proliferation, IFN-&#x003b3; and IL-10 secretion [<xref ref-type="bibr" rid="CR11">11</xref>] and the induction of tolerance and anergic T cells [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Blocking these inhibitory mechanisms resulted in enhanced anti-tumor immunity [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Recent data show that chemotherapeutic drugs affect not only the tumor cells but also the immunological tumor microenvironment resulting in a more robust anti-tumor response [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Widely used cytotoxic drugs such as doxorubicin, paclitaxel and gemcitabine have been shown to cause enhanced antigen cross-presentation, T-cell expansion and T-cell infiltration of tumors by to date unknown molecular mechanisms [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, our own studies show that oxaliplatin increased the T-cell stimulatory potential of monocyte-derived DCs (moDCs) by impairing the IL-4 induced upregulation of PD-L2 through dephosphorylation of STAT6 [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>In the present study, we disclose that oxaliplatin has a different effect on blood DC subsets. We observed that exposure to platinum-based chemotherapeutics increased the T-cell inhibitory molecule PD-L1 on TLR9-activated human pDCs resulting in decreased T-cell proliferation. Furthermore, platinum-based chemotherapeutics markedly increased TLR9-induced type I IFN secretion and decreased the expression of STAT1 and STAT3 and the secretion of IL-6 and TNF&#x003b1; by human pDCs.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Material and methods</title><sec id="Sec3"><title>Cells</title><p>Buffy coats were obtained from healthy volunteers with informed consent according to institutional and international guidelines. PDCs were purified by positive isolation using anti-BDCA-4-conjugated magnetic microbeads, and BDCA-1 mDCs were purified using anti-CD1c-conjugated microbeads (both Miltenyi Biotec, Bergisch-Gladbach, Germany) after B cell depletion. Thereafter, both cell types were adjusted to 10<sup>6</sup> cells/ml in X-VIVO-15 (Lonza, Verviers, Belgium) supplemented with 2% human serum (Sanquin, Nijmegen, the Netherlands). PDC and mDC purity was routinely up to 95%, as assessed by double staining with BDCA-2/CD123 or CD11c/CD1c (all Miltenyi Biotec). PDCs were activated through the addition of 5&#x000a0;&#x003bc;g/ml ODN-CpG-C (M362, Axxora, San Diego, CA) or 4&#x000a0;&#x003bc;g/ml R848 (Axxora, San Diego, CA). Monocyte-derived DCs (moDCs) were generated from adherent peripheral blood mononuclear cells (PBMCs), by culturing in the presence of IL-4 (500 U/ml) and GM-CSF (800 U/ml) (both Cellgenix, Freiburg, Germany). Cells were cultured in X-VIVO 15 medium supplemented with 2% of human serum and harvested on day 6 as immature DC. Immature DC or mDCs were activated through the addition of 4&#x000a0;&#x003bc;g/ml R848 and/or 20&#x000a0;&#x003bc;g/ml Poly I:C (Sigma-Aldrich). Oxaliplatin was added during DC activation, as indicated.</p></sec><sec id="Sec4"><title>Flow cytometry</title><p>Purity of pDCs and mDCs after isolation and the phenotype of the pDC populations were determined by flow cytometry. The following primary monoclonal antibodies (mAbs) and the appropriate isotype controls were used: anti-BDCA2-PE and CD123-APC (all Miltenyi Biotec); mIgG1-PE, mIgG1-APC, anti-HLA-ABC-PE (W6/32), anti-HLA-DR/DP-FITC (Q5/13), anti-CD40-PE, anti-CD80-PE, anti-CD86-PE, anti-CD86-APC, anti-PD-L1-PE, anti-PD-L2-PE, (all BD Bioscience Pharmingen, San Diego, CA, USA); anti-CD83-PE (Beckman Coulter, Mijdrecht, the Netherlands). <italic>Intracellular staining for STAT proteins:</italic> PDCs were harvested using TEN harvest buffer and fixed with 4% formaldehyde by 10-min incubation at 37&#x000b0;. Cells were permeabilized by incubating with ice-cold 90% methanol for 30&#x000a0;min on ice. Permeabilized cells were washed and incubate with the following primary antibodies: rabbit-polyclonal-anti-STAT1, rabbit-polyclonal-anti-pSTAT1, rabbit-polyclonal-anti-STAT2, rabbit-polyclonal-anti-pSTAT2, rabbit-monoclonal-anti-STAT3, rabbit-monoclonal-anti-pSTAT3, rabbit-polyclonal-anti-STAT6 (all from Cell Signaling) and goat-polyclonal-anti-pSTAT6 (BD Bioscience). Cells were washed twice and incubated with goat-anti-mouse-Alexa647 or goat-anti-rabbit-Alexa647 as secondary antibodies. Mean fluorescence intensity and percentage of positive cells were determined by flow cytometry on a FACSCalibur (BD Biosciences, San Jose, CA, USA).</p></sec><sec id="Sec5"><title>Mixed lymphocyte reaction</title><p>Allogeneic peripheral blood lymphocytes (PBLs) were co-cultured with differently matured pDCs, mDCs and moDCs in a 96-well round-bottom plate (pDC/PBL ratio 1:20 with 1&#x000a0;*&#x000a0;10<sup>5</sup> PBL). After 4&#x000a0;days of culture, 1&#x000a0;&#x003bc;Ci/well ([0.037&#x000a0;MBq]/well; MP Biomedicals, Amsterdam, the Netherlands) of tritiated thymidine was added for 8&#x000a0;h and incorporation was measured in a beta-counter. In some experiments, blocking antibodies against PD-L1 (e-Bioscience, San Diego, USA) were added to the culture at a final concentration of 10&#x000a0;&#x003bc;g/ml. Normal mouse serum was used as isotype control. Antibodies against PD-L1 were preincubated with pDCs for 30&#x000a0;min before adding PBLs. T-cell proliferation data were normalized to account for intra-experimental differences.</p></sec><sec id="Sec6"><title>Cytokine detection</title><p>PDCs and mDCs were cultured overnight at a concentration of 10<sup>5</sup> DCs/100&#x000a0;&#x003bc;l/well in a 96-well round-bottom plate. Supernatants were collected from DC cultures after 16&#x000a0;h of activation, and IFN&#x003b1; and IL-6 production was analyzed by murine monoclonal capture and HRP-conjugated anti-IFN&#x003b1; antibodies (Bender MedSystems, Vienna, Austria) or anti-IL-6 Abs (Sanquin, Amsterdam, the Netherlands) using standard ELISA procedures. TNF&#x003b1;, RANTES, IP-10 and MIP-1&#x003b1; production was measured using a human Multiplex kit (Bender MedSystems) according to manufacturer&#x02019;s instructions.</p></sec><sec id="Sec7"><title>Preparation of protein lysates and Western blotting</title><p>2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells were lysed in 20&#x000a0;&#x003bc;l lysis buffer containing 10&#x000a0;mM Tris/HCl pH 7.8, 5&#x000a0;mM EDTA, 50&#x000a0;mM NaCl, 1&#x000a0;mM Na<sub>3</sub>VO<sub>4</sub> 10&#x000a0;mM pyrophosphate, 50&#x000a0;mM NaF, 1% Triton X-100, 1&#x000a0;mM PMSF, 10&#x000a0;&#x003bc;g/ml aprotinin, 10&#x000a0;&#x003bc;g/ml leupeptin and 1X Roche protease inhibitor cocktail (Roche Diagnostics Nederland BV, Almere, the Netherlands). Samples were subjected to polyacrylamide gel electrophoresis and further processed for Western blot analysis. After blocking, membranes were incubated with one the following antibodies: mouse-monoclonal-anti-&#x003b2;-actin (1:20,000; Sigma-Aldrich, St. Louis, MO), purified mouse-anti-PTP1C/Shp-1 (1:250; BD), rabbit-polyclonal-anti-STAT1, rabbit-polyclonal-anti-pSTAT1, rabbit-monoclonal-anti-STAT3 and rabbit-monoclonal-anti-pSTAT3 (all from Cell Signaling). After washing, the membranes were incubated with one of the goat-anti-mouseIRDye800CW (LI-COR Biosciences, Lincoln, NE) or polyclonal goat-anti-rabbitAlexaFluor-680 (Molecular Probes, Eugene, OR) as secondary antibody and analyzed with the LICOR Odyssey Imaging system (LI-COR Biosciences). Integrated intensities were analyzed using Excel (Microsoft Corp., Redmond, WA).</p></sec><sec id="Sec8"><title>Statistics</title><p>All experiments were performed at least three times and results are shown as the mean&#x000a0;&#x000b1;&#x000a0;SEM. Data sets were either tested by a Student&#x02019;s <italic>t</italic> test or by one-way ANOVA followed by Newman&#x02013;Keuls or Dunnett&#x02019;s multiple comparison test.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Oxaliplatin differentially regulates the allostimulatory capacity of activated human DC subsets</title><p>When moDCs were exposed to the platinum-based chemotherapeutic compound oxaliplatin during activation, significantly higher T-cell proliferation was induced compared to moDCs activated without the addition of oxaliplatin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a and [<xref ref-type="bibr" rid="CR24">24</xref>]). Since oxaliplatin is given intravenously to cancer patients, this finding prompted us to investigate the effect of this drug on blood DC function.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Effect of oxaliplatin on DC allostimulatory capacity. Proliferation of T cells was measured by <sup>3</sup>H-thymidine incorporation and depicted as counts per minute. 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> peripheral blood leukocytes were stimulated for 4&#x000a0;days with 5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> allogeneic <bold>a</bold> moDCs activated through the addition of R848&#x000a0;+&#x000a0;Poly I:C or <bold>b</bold> CD1c<sup>+</sup> mDCs activated through the addition of either R848 or Poly I:C <bold>c</bold> pDCs activated through R848 or CpG-C. Where indicated, DCs were treated with oxaliplatin during activation. Data are the mean values&#x000a0;&#x000b1;&#x000a0;SEM of six measurements of at least three independent experiments with different donors (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001)</p></caption><graphic xlink:href="262_2011_1189_Fig1_HTML" id="MO1"/></fig></p><p>In contrast to what we observed for moDCs, both Poly I:C (TLR3)- and R848 (TLR7/8)-activated CD1c<sup>+</sup> mDCs induced lower allogeneic T-cell proliferation when oxaliplatin was present during activation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). In line with TLR-activated mDCs, we observed that pDCs activated with the TLR9 agonist CpG-C in the presence of oxaliplatin displayed a significantly decreased capacity to induce allogeneic T-cell responses (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Intriguingly, this effect was only observed when pDCs were activated through the TLR9 signaling pathway using CpG-C but not through TLR7/8 signaling using the single stranded RNA analog R848 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Oxaliplatin-treated pDCs displayed similar viability compared to oxaliplatin-treated moDCs (Suppl. Figure&#x000a0;1A, B), showing that the decreased T-cell proliferation is not caused by toxicity. Thus, oxaliplatin impairs the ability of TLR-activated blood DCs but not TLR7-activated pDCs to induce allogeneic T-cell responses.</p></sec><sec id="Sec11"><title>Oxaliplatin differentially affects the TLR-induced cytokine secretion profile of blood DCs</title><p>Next, we determined whether oxaliplatin modulates TLR-induced proinflammatory cytokine and chemokine secretion by pDCs and mDCs. Our results show that oxaliplatin negatively affected the secretion of IL-6, TNF-&#x003b1;, IP-10 and RANTES by TLR8-activated mDCs (Suppl. Figure&#x000a0;2A), TLR7-activated pDCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) and TLR9-activated pDCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). While oxaliplatin also negatively affected TLR3-induced IP-10 secretion by mDCs, it had no effect on other cytokine and chemokine secretion by TLR3-activated mDCs (Suppl. Figure&#x000a0;2B). Furthermore, TLR-induced MIP-1&#x003b1; by mDCs remained unaffected upon oxaliplatin treatment (Suppl. Figure&#x000a0;2A, 2B). By contrast, oxaliplatin treatment affected TLR-induced MIP-1&#x003b1; by pDCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b). A putative mechanism for the observed effects could lie in the modification of upstream players controlling NF-&#x003ba;B activity, since it controls IL-6, TNF&#x003b1;, RANTES, MIP-1&#x003b1; and IP-10 secretion. Interestingly, we found that oxaliplatin had a divergent effect on the TLR-induced IFN&#x003b1; secretion by pDCs. On the one hand, oxaliplatin treatment had no effect on TLR7-induced IFN&#x003b1; secretion, but it markedly increased TLR9-induced IFN&#x003b1; secretion by human pDCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Oxaliplatin alters the TLR-induced secretory profile in human pDCs. Supernatants of pDC cultures following incubation with R848 (<bold>a</bold>) or CpG-C (<bold>b</bold>) with or without 7&#x000a0;&#x003bc;g/ml oxaliplatin were analyzed for the presence IL-6, TNF&#x003b1;, IP-10, RANTES, MIP-1&#x003b1; and IFN&#x003b1;. The graphs show cytokine and chemokine production relative to pDCs activated in the absence oxaliplatin. Data shown are mean values&#x000a0;&#x000b1;&#x000a0;SEM of at least three independent experiments with different donors (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic xlink:href="262_2011_1189_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Oxaliplatin modulates the TLR-induced human blood DC phenotype</title><p>The observations that oxaliplatin affects TLR-induced cytokine secretion and decreased blood DC allostimulatory capacity prompted us to investigate whether oxaliplatin had an effect on the phenotype of blood DCs. As expected, CpG-C, R848 and Poly I:C induced a complete activated phenotype characterized by upregulation of CD40, CD80, CD86, CD83, and MHC class I and II (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Suppl. Figure&#x000a0;3). Oxaliplatin modestly enhanced TLR-induced upregulation of CD40 on mDCs, but had no effect on TLR-induced upregulation of MHC class I and II (Suppl. Figure&#x000a0;3A, B). Oxaliplatin did not affect expression levels of CD40 and the molecules MHC class I and II on TLR-activated pDCs (Suppl. Figure&#x000a0;3C, 3D). However, oxaliplatin together with CpG-C significantly increased the expression levels of the maturation marker CD83 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). By contrast, R848- and Poly I:C-induced CD83 expression was decreased after oxaliplatin treatment on pDCs and mDCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a&#x02013;c). While oxaliplatin enhanced R848- and Poly I:C-induced CD86 expression on mDCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b), it impaired CpG-C-induced CD86 upregulation on pDCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c, d). Furthermore, oxaliplatin also impaired R848- and CpG-C-induced CD80 expression on pDCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d), although CD80 expression on mDCs and R848-activated pDCs remained unaffected (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a&#x02013;c). These findings demonstrated that oxaliplatin differentially modulated the TLR3-, TLR7/8- and TLR9-induced blood DC phenotype.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Oxaliplatin modulates the TLR-induced human blood DC phenotype. Freshly isolated CD1c<sup>+</sup> mDCs and pDCs were activated overnight with either R848 or Poly I:C, for mDCs, and with R848 or CpG-C, for pDCs, with or without 7&#x000a0;&#x003bc;g/ml oxaliplatin. Histograms show the TLR-induced receptor expression levels of the surface molecules CD80, CD83 and CD86 on pDCs/mDCs (<italic>gray filled</italic>) compared to expression levels of oxaliplatin-treated TLR-activated pDCs/mDCs (<italic>thick black lines</italic>) and the appropriate isotype control (<italic>thin black line</italic>). Graphs show the receptor expression levels of the surface molecules CD80, CD83 and CD86 of activated pDCs/mDCs relative to R848 (<bold>a</bold>), Poly I:C (<bold>b</bold>) activated mDCs or R848 (<bold>c</bold>), CpG-C (<bold>d</bold>) activated pDCs. Data shown are mean values&#x000a0;&#x000b1;&#x000a0;SEM of at least three independent experiments with different donors (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic xlink:href="262_2011_1189_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Enhanced PD-L1 expression on pDCs after oxaliplatin treatment results in impaired T-cell activation</title><p>Besides T-cell stimulatory mechanisms, DCs are also known to express and utilize a variety of T-cell inhibitory mechanisms. Previously, we demonstrated that the enhanced T-cell proliferation was due to the downregulation of PD-L2 receptor expression levels on moDCs [<xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, as we evaluated the effect of oxaliplatin on TLR9-activated pDCs, we found that PD-L1 expression was increased upon exposure with oxaliplatin (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b), while PD-L2 expression and other inhibitory molecules were not detected under any of the conditions tested (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b and data not shown). By contrast, PD-L1 expression levels remained unaltered upon TLR3 and TLR7/8 stimulation and oxaliplatin treatment on pDCs and mDCs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). Inhibition of PD-L1 signaling pathway by addition of anti-PD-L1 blocking antibodies rescued the lost capacity of platinum-treated CpG-C-activated pDCs to stimulate allogeneic T cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). These data support the observation that upregulation of PD-L1 has a significant role on the decreased T-cell stimulatory capacity of platinum-treated pDCs. Thus, enhanced PD-L1 and decreased CD80/CD86 expression on oxaliplatin-treated CpG-C-activated pDCs impairs T-cell proliferation.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>TLR9-induced PD-L1 expression is enhanced by oxaliplatin on human pDCs. PD-L1 and PD-L2 expression by pDCs activated overnight with R848 or CpG-C with or without 7&#x000a0;&#x003bc;g/ml oxaliplatin. <bold>a</bold> Graphs show the PD-L1 receptor expression (MFI) by TLR-activated pDCs/mDC with or without oxaliplatin. Data shown are mean values of at least three independent experiments&#x000a0;&#x000b1;&#x000a0;SEM. <bold>b</bold> Histograms show the expression levels of PD-L1 and PD-L2 (<italic>dark gray filled</italic><italic>histograms</italic>) compared to isotype controls (<italic>light gray filled</italic><italic>histograms</italic>) on TLR9-activated pDCs, of one representative experiment. <bold>c</bold> Mixed lymphocyte reaction with CpG-C-activated pDCs in the presence or absence of 7&#x000a0;&#x003bc;g/ml oxaliplatin in the presence of blocking antibodies against PD-L1 or control IgG. Data shown are mean values&#x000a0;&#x000b1;&#x000a0;SEM of four independent experiments performed with different donors. The effect of PD-L1 blocking in the various conditions was compared to CpG-C-activated pDCs with IgG control antibodies that was set to 100% (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic xlink:href="262_2011_1189_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>IL-4 counterbalances oxaliplatin-induced TLR modulation in pDCs</title><p>Recently, we showed that pDCs stimulated with IL-4 together with a TLR9 agonist induced stronger allogeneic T-cell responses than pDCs stimulated solely through TLR9 [<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, we sought to determine whether IL-4 could restore the decreased allostimulatory capacity of oxaliplatin-treated pDCs. In accordance with previous findings, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a illustrates that IL-4 enhanced the allostimulatory capacity of TLR9-activated pDCs. Interestingly, the addition of IL-4 during oxaliplatin treatment could partially restore the low allogeneic T-cell proliferation by TLR9-activated pDCs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Additionally, we also observed that IL-4 was able to restore the oxaliplatin-impaired CD80 and CD86 expression to basal levels (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). This is in contrast to PD-L1 expression which remained high upon IL-4 stimulation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). Besides inverting the allostimulatory capacity and expression of surface molecules, IL-4 also reduced the oxaliplatin-enhanced IFN&#x003b1; secretion (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c). These data not only demonstrate that different environmental factors can modulate the functionality of TLR9-activated pDCs but also show that different environmental cues can counteract each other during TLR9 activation. Furthermore, these data also show that the balance between stimulatory and inhibitory signals provided by pDCs has a significant effect on T-cell proliferation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>IL-4 counterbalances oxaliplatin effects. Freshly isolated pDCs were activated overnight through CpG-C in the presence or absence of IL-4 and/or 7&#x000a0;&#x003bc;g/ml oxaliplatin. <bold>a</bold> Mixed lymphocyte reaction with CpG-C-activated pDCs in the presence and/or absence of oxaliplatin and IL-4. Data shown are mean values&#x000a0;&#x000b1;&#x000a0;SEM of four independent experiments performed with different donors and normalized to CpG-C-activated pDCs. Graphs show the surface receptor expression of <bold>b</bold> CD80, CD86 and PD-L1 and <bold>c</bold> IFN&#x003b1; secretion by CpG-C-activated pDCs in the presence and/or absence of oxaliplatin and IL-4. <bold>d</bold> Model; TLR-9-induced activation of human pDCs can be altered by the presence of environmental cues, resulting in an enhanced or decreased expression profile of costimulatory and co-inhibitory molecules. This converted balance leads to more tolerogenic or immunogenic pDCs that largely influence the fate of the T-cell response (*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</p></caption><graphic xlink:href="262_2011_1189_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>Oxaliplatin impairs TLR9-induced STAT1 and STAT3 expression</title><p>Recently, An et al. described that SHP-1 differentially regulates the production of proinflammatory cytokines and type I interferon [<xref ref-type="bibr" rid="CR26">26</xref>]. Therefore, we studied the potential involvement of phosphatases in order to pinpoint the potential candidate proteins responsible for the observed dual function of oxaliplatin on pDCs: an enhanced IFN&#x003b1; secretion and a decreased NF-&#x003ba;B-induced response. We hypothesized that oxaliplatin treatment might increase SHP-1 expression in human TLR9-activated pDCs. In Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, it is shown that SHP-1 expression is induced in human pDCs upon TLR9 activation with CpG-C. However, oxaliplatin in combination with CpG-C did not result in significant enhanced SHP-1 expression (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, b). Because the functional activity of SHP-1 does not have a linear relation with its expression [<xref ref-type="bibr" rid="CR27">27</xref>], we also investigated the effect of SHP-1 inhibition using the inhibitor sodium stibogluconate. To exclude the involvement of other phosphatases, we also tested the broad range phosphatase inhibitor suramin [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The presence of sodium stibogluconate reduced the oxaliplatin-induced IFN&#x003b1; secretion, but did not affect oxaliplatin-induced CD80, CD86 and PD-L1 expression (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). Interestingly, there was an increase in the effect of oxaliplatin in the presence of suramin hinting to the possibility that a phosphatase is involved (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). Another recent study reported that oxaliplatin activates the NOTCH-1 pathway by induction of the &#x003b3;-secretase complex [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, we investigated the effect of pDC preincubation with a &#x003b3;-secretase inhibitor on oxaliplatin-induced effects. However, this inhibitor did not result in abrogation of the oxaliplatin-induced effects (data not shown).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Oxaliplatin decreases TLR9-induced STAT1 and STAT3 expression. <bold>a</bold> 2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells were left untreated or activated with CpG-C or activated with CpG-C with or without oxaliplatin (7&#x000a0;&#x003bc;g/ml). After overnight culture, cells were lysed and SHP-1 expression was analyzed by Western blot. Data shown are of one representative experiment. <bold>b</bold> The graph shows SHP-1 expression by pDCs relative CpG-C-activated pDCs. SHP-1 expression relative to actin was quantified as described in methods. Data shown are mean values of three independent experiments&#x000a0;&#x000b1;&#x000a0;SEM. <bold>c</bold> PDCs were activated overnight by CpG-C with or without oxaliplatin and phosphatase inhibitors where indicated. The graphs show CD80, CD86 and PD-L1 surface expression levels and IFN&#x003b1; secretion by pDCs relative to CpG-C-activated pDCs. Data shown are mean values of three independent experiments&#x000a0;&#x000b1;&#x000a0;SEM. <bold>d</bold> Freshly isolated, CpG-C-activated &#x000b1; oxaliplatin pDCs were lysed, and total and phosphorylated STAT1 and STAT3 expression was analyzed by Western blot. One representative experiment is shown. <bold>e</bold> Histograms show the expression of total or phosphorylated STAT1, STAT2, STAT3 and STAT6 after overnight activation with CpG-C (<italic>gray filled</italic>; <italic>top</italic> and <italic>middle row</italic>) in the presence of oxaliplatin (<italic>thick black lines</italic>; <italic>top</italic> and <italic>bottom row</italic>) or IL-4 (<italic>thick black lines</italic>; <italic>middle row</italic>: <italic>gray filled; bottom row</italic>). One representative experiment is shown</p></caption><graphic xlink:href="262_2011_1189_Fig6_HTML" id="MO6"/></fig></p><p>Previously, Lesterhuis et al. demonstrated that oxaliplatin was able to dephosphorylate STAT6 [<xref ref-type="bibr" rid="CR24">24</xref>]. That prompted us to investigate whether oxaliplatin also affects STAT signaling in TLR9-activated pDCs. We showed by both Western blot and FACS analysis that oxaliplatin reduced expression levels of total STAT1 and STAT3 in TLR9-activated human pDCs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d, e). However, total STAT2, STAT6 and expression of all phosphorylated STATs remained unaffected upon oxaliplatin treatment in TLR9-activated pDCs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d, e). In addition to oxaliplatin, we also sought to determine the TLR9-induced STAT expression upon IL-4 exposure. As expected, IL-4 induced the phosphorylation STAT6 and STAT3, whereas expression and phosphorylation of other STATs remained unaltered (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e). Besides reducing the expression of total STAT1 and STAT3, oxaliplatin also impaired the IL-4 induced phosphorylation of STAT6 and STAT3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e). All together, these data show that oxaliplatin affects STAT1 and STAT3 expression and TLR9-induced signaling.</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>Recent studies show that besides having a direct cytotoxic effect on tumor cells, chemotherapeutic drugs can also potentiate the immune system [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Here, we show that the chemotherapeutic platinum compound oxaliplatin modulated TLR9-induced signaling in human pDCs. This modulation led to increased IFN&#x003b1; production, decreased inflammatory cytokine and chemokine secretion, and decreased STAT1 and STAT3 expression by human pDCs. Furthermore, we showed that oxaliplatin enhanced PD-L1 expression levels on pDCs, resulting in impaired T-cell proliferation depending on the maturation stimuli. Generally, oxaliplatin is used in combination with other cytotoxic drugs as a treatment regimen for gastrointestinal, colorectal, esophago-gastric and/or pancreatic cancer. However, it remains to be elucidated whether the other active compounds in these treatment regimens may also affect the immunogenicity of human DC subsets.</p><p>We studied STATs and protein tyrosine phosphatases, which are key regulators of intracellular signaling as an obvious mechanism exploited by oxaliplatin to modulate TLR-induced signaling. The protein tyrosine phosphatases SHP-1 was reported to block TLR-induced production of proinflammatory cytokines by inhibiting the activation of NF-&#x003ba;B pathway and MAPKs by direct dephosphorylation [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Moreover, An et al. recently described that in mice SHP-1 increased TLR- and RIG-I-induced type I IFN production by directly binding to the kinase domain of IRAK1 and thus inhibiting IRAK1 activity in bone marrow DCs, peritoneal macrophages and splenic CD11c<sup>+</sup> DCs [<xref ref-type="bibr" rid="CR26">26</xref>]. We obtained the same observations in the TLR9-induced cytokine secretion profile after oxaliplatin treatment; however, a role for SHP-1 was excluded based on experiments which showed that sodium stibogluconate had no effect. Interestingly, suramin, a broad phosphatase inhibitor, enhanced the oxaliplatin-induced effects. These data indicate that oxaliplatin impairs the activity of a certain phosphatase rather than increasing the expression of a phosphatase. Besides phosphatases, also kinases are involved in signaling upon ligand binding by TLRs [<xref ref-type="bibr" rid="CR33">33</xref>]. Larang&#x000e9; et al. demonstrated that using specific inhibitors for JNK or JAK upon TLR7 or TLR8 stimulation, significant changes were observed in the expression of certain surface molecules and the production cytokines [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings underscore that inhibition of mediators involved in downstream signaling after TLR stimulation has subtle but significant influences on cell functionality. The observed increased expression of PD-L1 related to oxaliplatin treatment implicates undesired effects on the immunological elimination of tumor cells outcome in cancer patients. It was reported that tumor-infiltrating dendritic cells which express PD-L1 help to maintain the immunosuppressive environment [<xref ref-type="bibr" rid="CR10">10</xref>]. PD-L1 expression has also been detected on the surface of a wide variety of human cancers, including lung, colon, breast, ovary, renal cell, glioma and melanoma [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], and has been correlated with poor prognosis [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. Tumors escape from the host immune system by attenuation of tumor-specific T-cell responses via PD-L1/PD-1 interactions. Normally, PD-L1 expression is controlled by STAT3 and becomes upregulated by tumor cells and other immune cells upon IFN or IL-6 stimulation [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. Recently, a study showed that chemotherapeutic agents also induced PD-L1 surface expression in breast cancer cells and promoted PD-L1-mediated T-cell apoptosis [<xref ref-type="bibr" rid="CR44">44</xref>]. Additionally, we found that other platinum-based chemotherapeutic also induced PD-L1 and decreased CD80 and CD86 expression on pDCs, and that oxaliplatin also induced PD-L1 expression on tumor cells (Suppl. Figure&#x000a0;4). In summary, the expression of PD-L1 on tumors has a negative effect on the immunological outcome and is considered as a key feature of tolerogenic DCs [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>In the present study, we demonstrated that human pDCs, treated with oxaliplatin in the presence of TLR9-induced type I IFN, markedly increased expression levels of PD-L1. Aspord et al. demonstrated that in breast cancer tumors CD4<sup>+</sup> T cells are present secreting IFN&#x003b3; and IL-13 [<xref ref-type="bibr" rid="CR45">45</xref>]. These T cells provide an additional source of IFNs which in combination with chemotherapeutic agents can lead to enhanced PD-L1 expression on either tumor cells or on tumor-infiltrating pDCs. Moreover, infiltration of pDCs and expression of PD-L1 in severable tumors correlated with poor prognosis. Recently, Lesterhuis et al. described that platinum compounds positively affect the immunostimulatory potential of myeloid DCs by impairing the upregulation of PD-L2 [<xref ref-type="bibr" rid="CR24">24</xref>]. Together, this demonstrates that platinum compounds have dissimilar effects on different DC subsets dependent on the presence of environmental cues. In cancer patients, the therapeutic off-target effect of platinum compounds will depend on the presence and the amount of the different tumor-infiltrating DC subsets, the TLR expression on those DC subsets, and the micro-environment in which they reside. Based on the present study, when tumors are infiltrated with high numbers of pDCs, it would be beneficial to provide additional TLR7-agonists rather than TLR9-agonists in combination with platinum-based chemotherapeutics. Combining chemo- with immunotherapy is already reported, showing that combining chemotherapy with immunotherapy improves patient survival compared to patients treated with only chemotherapy [<xref ref-type="bibr" rid="CR46">46</xref>]. However, in order to become even more effective, therapeutic strategies should have direct cytotoxic effects but also be tailored based on the presence of tumor-infiltrating DCs and the TLR expression by those tumor-infiltrating DCs. This tailor-made combination of chemotherapy with additional immunotherapy has great potential in inducing superior anti-tumor responses and ultimately will lead to enhanced tumor clearance and patient survival.</p></sec><sec sec-type="supplementary-material" id="AppESM1"><title>Electronic supplementary material</title><sec id="SecESM1"><p><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="262_2011_1189_MOESM1_ESM.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Supplementary material 1 (PDF 622 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><ack><p>This work was supported by grants from the Dutch Cancer Society (KWF 2004-3127), The Netherlands Organization for Scientific Research (NWO ZonMW) (Vidi grant 91776363 to IJMdV), the vanderES Foundation 222 and a SPINOZA price to CGF.</p><sec id="d29e933"><title>Conflict of interest</title><p>The authors have no financial conflicts of interest.</p></sec><sec id="d29e938"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><year>1998</year><volume>392</volume><issue>6673</issue><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Tel</surname><given-names>J</given-names></name><name><surname>Sliepen</surname><given-names>KH</given-names></name><name><surname>Benitez-Ribas</surname><given-names>D</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Vries</surname><given-names>IJ</given-names></name></person-group><article-title>Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy</article-title><source>Cancer Immunol Immunother</source><year>2010</year><volume>59</volume><issue>10</issue><fpage>1573</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1007/s00262-010-0833-1</pub-id><pub-id pub-id-type="pmid">20204387</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Guastalla</surname><given-names>JP</given-names></name><name><surname>Bremond</surname><given-names>A</given-names></name><name><surname>Goddard</surname><given-names>S</given-names></name><name><surname>Pin</surname><given-names>JJ</given-names></name><name><surname>Barthelemy-Dubois</surname><given-names>C</given-names></name><name><surname>Lebecque</surname><given-names>S</given-names></name></person-group><article-title>Dendritic cell infiltration and prognosis of early stage breast cancer</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><issue>22</issue><fpage>7466</fpage><lpage>7474</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0684</pub-id><pub-id pub-id-type="pmid">15569976</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>E</given-names></name><name><surname>Wollenberg</surname><given-names>B</given-names></name><name><surname>Rothenfusser</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Wellisch</surname><given-names>D</given-names></name><name><surname>Mack</surname><given-names>B</given-names></name><name><surname>Giese</surname><given-names>T</given-names></name><name><surname>Gires</surname><given-names>O</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name></person-group><article-title>Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>19</issue><fpage>6478</fpage><lpage>6487</lpage><pub-id pub-id-type="pmid">14559840</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Machelon</surname><given-names>V</given-names></name><name><surname>Coulomb-L&#x02019;Hermin</surname><given-names>A</given-names></name><name><surname>Borvak</surname><given-names>J</given-names></name><name><surname>Nome</surname><given-names>F</given-names></name><name><surname>Isaeva</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Krzysiek</surname><given-names>R</given-names></name><name><surname>Durand-Gasselin</surname><given-names>I</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Pustilnik</surname><given-names>T</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Galanaud</surname><given-names>P</given-names></name><name><surname>Capron</surname><given-names>F</given-names></name><name><surname>Emilie</surname><given-names>D</given-names></name><name><surname>Curiel</surname><given-names>TJ</given-names></name></person-group><article-title>Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><issue>12</issue><fpage>1339</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1038/nm1201-1339</pub-id><pub-id pub-id-type="pmid">11726975</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Corak</surname><given-names>J</given-names></name><name><surname>Ciernik</surname><given-names>IF</given-names></name><name><surname>Kavanaugh</surname><given-names>D</given-names></name><name><surname>Carbone</surname><given-names>DP</given-names></name></person-group><article-title>Decreased antigen presentation by dendritic cells in patients with breast cancer</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><issue>3</issue><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">9815709</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menetrier-Caux</surname><given-names>C</given-names></name><name><surname>Montmain</surname><given-names>G</given-names></name><name><surname>Dieu</surname><given-names>MC</given-names></name><name><surname>Bain</surname><given-names>C</given-names></name><name><surname>Favrot</surname><given-names>MC</given-names></name><name><surname>Caux</surname><given-names>C</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name></person-group><article-title>Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor</article-title><source>Blood</source><year>1998</year><volume>92</volume><issue>12</issue><fpage>4778</fpage><lpage>4791</lpage><pub-id pub-id-type="pmid">9845545</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>D</given-names></name><name><surname>Chomarat</surname><given-names>P</given-names></name><name><surname>Broyles</surname><given-names>D</given-names></name><name><surname>Netto</surname><given-names>G</given-names></name><name><surname>Harb</surname><given-names>GM</given-names></name><name><surname>Lebecque</surname><given-names>S</given-names></name><name><surname>Valladeau</surname><given-names>J</given-names></name><name><surname>Davoust</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>KA</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas</article-title><source>J Exp Med</source><year>1999</year><volume>190</volume><issue>10</issue><fpage>1417</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1084/jem.190.10.1417</pub-id><pub-id pub-id-type="pmid">10562317</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Curiel</surname><given-names>T</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><article-title>Plasmacytoid dendritic cells induce CD8&#x000a0;+&#x000a0;regulatory T cells in human ovarian carcinoma</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>12</issue><fpage>5020</fpage><lpage>5026</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4043</pub-id><pub-id pub-id-type="pmid">15958543</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Krzysiek</surname><given-names>R</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Zimmermann</surname><given-names>MC</given-names></name><name><surname>David</surname><given-names>O</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Dhurandhar</surname><given-names>N</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Berggren</surname><given-names>R</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Emilie</surname><given-names>D</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><article-title>Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><issue>5</issue><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nm863</pub-id><pub-id pub-id-type="pmid">12704383</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Long</surname><given-names>AJ</given-names></name><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Bourque</surname><given-names>K</given-names></name><name><surname>Chernova</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Fitz</surname><given-names>LJ</given-names></name><name><surname>Malenkovich</surname><given-names>N</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Byrne</surname><given-names>MC</given-names></name><name><surname>Horton</surname><given-names>HF</given-names></name><name><surname>Fouser</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>L</given-names></name><name><surname>Ling</surname><given-names>V</given-names></name><name><surname>Bowman</surname><given-names>MR</given-names></name><name><surname>Carreno</surname><given-names>BM</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</article-title><source>J Exp Med</source><year>2000</year><volume>192</volume><issue>7</issue><fpage>1027</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1084/jem.192.7.1027</pub-id><pub-id pub-id-type="pmid">11015443</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keir</surname><given-names>ME</given-names></name><name><surname>Butte</surname><given-names>MJ</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>PD-1 and its ligands in tolerance and immunity</article-title><source>Annu Rev Immunol</source><year>2008</year><volume>26</volume><fpage>677</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090331</pub-id><pub-id pub-id-type="pmid">18173375</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Dorfman</surname><given-names>DM</given-names></name><name><surname>Ma</surname><given-names>FR</given-names></name><name><surname>Sullivan</surname><given-names>EL</given-names></name><name><surname>Munoz</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Greenfield</surname><given-names>EA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><article-title>Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><issue>3</issue><fpage>1257</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">12538684</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radhakrishnan</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>LT</given-names></name><name><surname>Ciric</surname><given-names>B</given-names></name><name><surname>Ure</surname><given-names>DR</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Tamada</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Tseng</surname><given-names>SY</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kyle</surname><given-names>RA</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Pease</surname><given-names>LR</given-names></name></person-group><article-title>Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><issue>4</issue><fpage>1830</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">12574348</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selenko-Gebauer</surname><given-names>N</given-names></name><name><surname>Majdic</surname><given-names>O</given-names></name><name><surname>Szekeres</surname><given-names>A</given-names></name><name><surname>Hofler</surname><given-names>G</given-names></name><name><surname>Guthann</surname><given-names>E</given-names></name><name><surname>Korthauer</surname><given-names>U</given-names></name><name><surname>Zlabinger</surname><given-names>G</given-names></name><name><surname>Steinberger</surname><given-names>P</given-names></name><name><surname>Pickl</surname><given-names>WF</given-names></name><name><surname>Stockinger</surname><given-names>H</given-names></name><name><surname>Knapp</surname><given-names>W</given-names></name><name><surname>Stockl</surname><given-names>J</given-names></name></person-group><article-title>B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><issue>7</issue><fpage>3637</fpage><lpage>3644</lpage><pub-id pub-id-type="pmid">12646628</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name></person-group><article-title>Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><issue>19</issue><fpage>12293</fpage><lpage>12297</lpage><pub-id pub-id-type="doi">10.1073/pnas.192461099</pub-id><pub-id pub-id-type="pmid">12218188</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>F</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ichikawa</surname><given-names>M</given-names></name><name><surname>Rietz</surname><given-names>C</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Lau</surname><given-names>JS</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Tamada</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>3</issue><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">15705911</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>The new B7&#x000a0;s: playing a pivotal role in tumor immunity</article-title><source>J Immunother</source><year>2007</year><volume>30</volume><issue>3</issue><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e31802e085a</pub-id><pub-id pub-id-type="pmid">17414316</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Bishop</surname><given-names>C</given-names></name><name><surname>Daugherty</surname><given-names>B</given-names></name><name><surname>Chute</surname><given-names>H</given-names></name><name><surname>Holst</surname><given-names>P</given-names></name><name><surname>Kurahara</surname><given-names>C</given-names></name><name><surname>Lott</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Welcher</surname><given-names>AA</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><article-title>Regulation of T cell activation and tolerance by PDL2</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><issue>31</issue><fpage>11695</fpage><lpage>11700</lpage><pub-id pub-id-type="doi">10.1073/pnas.0601347103</pub-id><pub-id pub-id-type="pmid">16864790</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>8</issue><fpage>2127</fpage><lpage>2130</lpage><pub-id pub-id-type="pmid">19620780</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lake</surname><given-names>RA</given-names></name><name><surname>Robinson</surname><given-names>BW</given-names></name></person-group><article-title>Immunotherapy and chemotherapy&#x02014;a practical partnership</article-title><source>Nat Rev</source><year>2005</year><volume>5</volume><issue>5</issue><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nrc1613</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>AK</given-names></name><name><surname>Lake</surname><given-names>RA</given-names></name><name><surname>Marzo</surname><given-names>AL</given-names></name><name><surname>Scott</surname><given-names>B</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Collins</surname><given-names>EJ</given-names></name><name><surname>Frelinger</surname><given-names>JA</given-names></name><name><surname>Robinson</surname><given-names>BW</given-names></name></person-group><article-title>Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><issue>10</issue><fpage>4905</fpage><lpage>4913</lpage><pub-id pub-id-type="pmid">12734333</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shurin</surname><given-names>GV</given-names></name><name><surname>Tourkova</surname><given-names>IL</given-names></name><name><surname>Kaneno</surname><given-names>R</given-names></name><name><surname>Shurin</surname><given-names>MR</given-names></name></person-group><article-title>Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><issue>1</issue><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900734</pub-id><pub-id pub-id-type="pmid">19535620</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Hato</surname><given-names>SV</given-names></name><name><surname>Eleveld-Trancikova</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>BJ</given-names></name><name><surname>Nierkens</surname><given-names>S</given-names></name><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Boer</surname><given-names>A</given-names></name><name><surname>Herpen</surname><given-names>CM</given-names></name><name><surname>Kaanders</surname><given-names>JH</given-names></name><name><surname>Krieken</surname><given-names>JH</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>Vries</surname><given-names>IJ</given-names></name></person-group><article-title>Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><issue>8</issue><fpage>3100</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1172/JCI43656</pub-id><pub-id pub-id-type="pmid">21765211</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tel</surname><given-names>J</given-names></name><name><surname>Torensma</surname><given-names>R</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name></person-group><article-title>IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><issue>4</issue><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/jid.2010.410</pub-id><pub-id pub-id-type="pmid">21191414</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><issue>5</issue><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/ni.1604</pub-id><pub-id pub-id-type="pmid">18391954</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinerman</surname><given-names>O</given-names></name><name><surname>Veiga</surname><given-names>J</given-names></name><name><surname>Dorfman</surname><given-names>JR</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name><name><surname>Altan-Bonnet</surname><given-names>G</given-names></name></person-group><article-title>Variability and robustness in T cell activation from regulated heterogeneity in protein levels</article-title><source>Science</source><year>2008</year><volume>321</volume><issue>5892</issue><fpage>1081</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.1158013</pub-id><pub-id pub-id-type="pmid">18719282</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>MK</given-names></name><name><surname>Yi</surname><given-names>T</given-names></name></person-group><article-title>Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><issue>6</issue><fpage>3391</fpage><lpage>3397</lpage><pub-id pub-id-type="pmid">11544330</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Keng</surname><given-names>YF</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>ZY</given-names></name></person-group><article-title>Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>20</issue><fpage>12281</fpage><lpage>12287</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.20.12281</pub-id><pub-id pub-id-type="pmid">9575179</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>RD</given-names></name><name><surname>Shelton</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Qin</surname><given-names>LX</given-names></name><name><surname>Notterman</surname><given-names>D</given-names></name><name><surname>Paty</surname><given-names>PB</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name></person-group><article-title>Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><issue>2</issue><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2088</pub-id><pub-id pub-id-type="pmid">19147571</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaled</surname><given-names>AR</given-names></name><name><surname>Butfiloski</surname><given-names>EJ</given-names></name><name><surname>Sobel</surname><given-names>ES</given-names></name><name><surname>Schiffenbauer</surname><given-names>J</given-names></name></person-group><article-title>Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B</article-title><source>Cell Immunol</source><year>1998</year><volume>185</volume><issue>1</issue><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1006/cimm.1998.1272</pub-id><pub-id pub-id-type="pmid">9636682</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandan</surname><given-names>D</given-names></name><name><surname>Lo</surname><given-names>R</given-names></name><name><surname>Reiner</surname><given-names>NE</given-names></name></person-group><article-title>Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with <italic>Leishmania donovani</italic></article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><issue>8</issue><fpage>4055</fpage><lpage>4063</lpage><pub-id pub-id-type="pmid">10417174</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larange</surname><given-names>A</given-names></name><name><surname>Antonios</surname><given-names>D</given-names></name><name><surname>Pallardy</surname><given-names>M</given-names></name><name><surname>Kerdine-Romer</surname><given-names>S</given-names></name></person-group><article-title>TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation</article-title><source>J Leukoc Biol</source><year>2009</year><volume>85</volume><issue>4</issue><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1189/jlb.0808504</pub-id><pub-id pub-id-type="pmid">19164127</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Strome</surname><given-names>SE</given-names></name><name><surname>Salomao</surname><given-names>DR</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Hirano</surname><given-names>F</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Roche</surname><given-names>PC</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Tamada</surname><given-names>K</given-names></name><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><issue>8</issue><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">12091876</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wintterle</surname><given-names>S</given-names></name><name><surname>Schreiner</surname><given-names>B</given-names></name><name><surname>Mitsdoerffer</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Meyermann</surname><given-names>R</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name></person-group><article-title>Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>21</issue><fpage>7462</fpage><lpage>7467</lpage><pub-id pub-id-type="pmid">14612546</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohigashi</surname><given-names>Y</given-names></name><name><surname>Sho</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Tsurui</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Yoriki</surname><given-names>R</given-names></name><name><surname>Kashizuka</surname><given-names>H</given-names></name><name><surname>Yane</surname><given-names>K</given-names></name><name><surname>Tsushima</surname><given-names>F</given-names></name><name><surname>Otsuki</surname><given-names>N</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>Y</given-names></name></person-group><article-title>Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>8</issue><fpage>2947</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1469</pub-id><pub-id pub-id-type="pmid">15837746</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamanishi</surname><given-names>J</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name></person-group><article-title>Programmed cell death 1 ligand 1 and tumor-infiltrating CD8&#x000a0;+&#x000a0;T lymphocytes are prognostic factors of human ovarian cancer</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>9</issue><fpage>3360</fpage><lpage>3365</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611533104</pub-id><pub-id pub-id-type="pmid">17360651</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Mackensen</surname><given-names>A</given-names></name></person-group><article-title>Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy</article-title><source>Cancer Immunol Immunother</source><year>2005</year><volume>54</volume><issue>4</issue><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0593-x</pub-id><pub-id pub-id-type="pmid">15599732</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>RH</given-names></name><name><surname>Gillett</surname><given-names>MD</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Webster</surname><given-names>WS</given-names></name><name><surname>Krejci</surname><given-names>KG</given-names></name><name><surname>Lobo</surname><given-names>JR</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Strome</surname><given-names>SE</given-names></name><name><surname>Leibovich</surname><given-names>BC</given-names></name><name><surname>Kwon</surname><given-names>ED</given-names></name></person-group><article-title>Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><issue>49</issue><fpage>17174</fpage><lpage>17179</lpage><pub-id pub-id-type="doi">10.1073/pnas.0406351101</pub-id><pub-id pub-id-type="pmid">15569934</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>I</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name><name><surname>Spiotto</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><article-title>PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8&#x000a0;+&#x000a0;T cells</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>3</issue><fpage>1140</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3259</pub-id><pub-id pub-id-type="pmid">14871849</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Akiba</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Tanno</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name></person-group><article-title>Expression of programmed death 1 ligands by murine T cells and APC</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><issue>10</issue><fpage>5538</fpage><lpage>5545</lpage><pub-id pub-id-type="pmid">12421930</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumpter</surname><given-names>TL</given-names></name><name><surname>Thomson</surname><given-names>AW</given-names></name></person-group><article-title>The STATus of PD-L1 (B7-H1) on tolerogenic APCs</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>2</issue><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/eji.201041353</pub-id><pub-id pub-id-type="pmid">21267998</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfle</surname><given-names>SJ</given-names></name><name><surname>Strebovsky</surname><given-names>J</given-names></name><name><surname>Bartz</surname><given-names>H</given-names></name><name><surname>Sahr</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>C</given-names></name><name><surname>Kaiser</surname><given-names>C</given-names></name><name><surname>Dalpke</surname><given-names>AH</given-names></name><name><surname>Heeg</surname><given-names>K</given-names></name></person-group><article-title>PD-L1 expression on tolerogenic APCs is controlled by STAT-3</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>2</issue><fpage>413</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1002/eji.201040979</pub-id><pub-id pub-id-type="pmid">21268011</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Su</surname><given-names>DM</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name></person-group><article-title>Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis</article-title><source>Mol Immunol</source><year>2008</year><volume>45</volume><issue>5</issue><fpage>1470</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2007.08.013</pub-id><pub-id pub-id-type="pmid">17920123</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspord</surname><given-names>C</given-names></name><name><surname>Pedroza-Gonzalez</surname><given-names>A</given-names></name><name><surname>Gallegos</surname><given-names>M</given-names></name><name><surname>Tindle</surname><given-names>S</given-names></name><name><surname>Burton</surname><given-names>EC</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Marches</surname><given-names>F</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name></person-group><article-title>Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4&#x000a0;+&#x000a0;T cells that facilitate tumor development</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><issue>5</issue><fpage>1037</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1084/jem.20061120</pub-id><pub-id pub-id-type="pmid">17438063</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manegold</surname><given-names>C</given-names></name><name><surname>Gravenor</surname><given-names>D</given-names></name><name><surname>Woytowitz</surname><given-names>D</given-names></name><name><surname>Mezger</surname><given-names>J</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>Albert</surname><given-names>G</given-names></name><name><surname>Al-Adhami</surname><given-names>M</given-names></name><name><surname>Readett</surname><given-names>D</given-names></name><name><surname>Krieg</surname><given-names>AM</given-names></name><name><surname>Leichman</surname><given-names>CG</given-names></name></person-group><article-title>Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>24</issue><fpage>3979</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.5807</pub-id><pub-id pub-id-type="pmid">18711188</pub-id></mixed-citation></ref></ref-list><glossary><def-list><def-list><def-item><term>DC</term><def><p>Dendritic cell</p></def></def-item><def-item><term>moDC</term><def><p>Monocyte-derived DC</p></def></def-item><def-item><term>mDC</term><def><p>Myeloid DC</p></def></def-item><def-item><term>pDC</term><def><p>Plasmacytoid DC</p></def></def-item><def-item><term>PD-1</term><def><p>Death receptor 1</p></def></def-item><def-item><term>PD-L1</term><def><p>Program death ligand 1</p></def></def-item></def-list></def-list></glossary></back></article>